ES2679245T3 - Vacuna contra la infección por beta-herpesvirus y uso de la misma - Google Patents
Vacuna contra la infección por beta-herpesvirus y uso de la misma Download PDFInfo
- Publication number
- ES2679245T3 ES2679245T3 ES11718950.6T ES11718950T ES2679245T3 ES 2679245 T3 ES2679245 T3 ES 2679245T3 ES 11718950 T ES11718950 T ES 11718950T ES 2679245 T3 ES2679245 T3 ES 2679245T3
- Authority
- ES
- Spain
- Prior art keywords
- nucleotide sequence
- herpesvirus
- beta
- seq
- sequence according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000015181 infectious disease Diseases 0.000 title claims description 39
- 229960005486 vaccine Drugs 0.000 title description 26
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 106
- 241000282414 Homo sapiens Species 0.000 claims abstract description 73
- 238000000034 method Methods 0.000 claims abstract description 22
- 230000002950 deficient Effects 0.000 claims abstract description 18
- 230000028993 immune response Effects 0.000 claims abstract description 16
- 238000011282 treatment Methods 0.000 claims abstract description 14
- 238000002255 vaccination Methods 0.000 claims abstract description 12
- 210000002845 virion Anatomy 0.000 claims abstract description 12
- 101150041636 NEC1 gene Proteins 0.000 claims abstract description 6
- 101150098384 NEC2 gene Proteins 0.000 claims abstract description 6
- 101150040913 DUT gene Proteins 0.000 claims abstract description 5
- 101150109586 Gk gene Proteins 0.000 claims abstract description 5
- 101150074007 UL99 gene Proteins 0.000 claims abstract description 3
- 230000001939 inductive effect Effects 0.000 claims abstract 2
- 239000002773 nucleotide Substances 0.000 claims description 459
- 125000003729 nucleotide group Chemical group 0.000 claims description 459
- 210000004027 cell Anatomy 0.000 claims description 41
- 108020004707 nucleic acids Proteins 0.000 claims description 37
- 102000039446 nucleic acids Human genes 0.000 claims description 37
- 150000007523 nucleic acids Chemical class 0.000 claims description 37
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims description 27
- 239000013598 vector Substances 0.000 claims description 21
- 230000003472 neutralizing effect Effects 0.000 claims description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 15
- 239000000427 antigen Substances 0.000 claims description 14
- 102000036639 antigens Human genes 0.000 claims description 14
- 108091007433 antigens Proteins 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 210000000822 natural killer cell Anatomy 0.000 claims description 7
- 229920001184 polypeptide Polymers 0.000 claims description 7
- 101100048372 Human cytomegalovirus (strain AD169) H301 gene Proteins 0.000 claims description 6
- 101100048373 Human cytomegalovirus (strain Merlin) UL18 gene Proteins 0.000 claims description 6
- 108091054437 MHC class I family Proteins 0.000 claims description 6
- 102000043129 MHC class I family Human genes 0.000 claims description 6
- 102000015636 Oligopeptides Human genes 0.000 claims description 6
- 108010038807 Oligopeptides Proteins 0.000 claims description 6
- 101150030723 RIR2 gene Proteins 0.000 claims description 6
- 101150037769 TRX2 gene Proteins 0.000 claims description 6
- 101150100826 UL40 gene Proteins 0.000 claims description 6
- 230000036755 cellular response Effects 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 5
- 210000000056 organ Anatomy 0.000 claims description 5
- 230000004044 response Effects 0.000 claims description 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 102000053642 Catalytic RNA Human genes 0.000 claims description 3
- 108090000994 Catalytic RNA Proteins 0.000 claims description 3
- 101100504458 Cercopithecine herpesvirus 9 (strain DHV) gI gene Proteins 0.000 claims description 3
- 101100263193 Gallid herpesvirus 2 (strain GA) US1206 gene Proteins 0.000 claims description 3
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims description 3
- 101150042088 UL16 gene Proteins 0.000 claims description 3
- 101150022492 UL83 gene Proteins 0.000 claims description 3
- 101150085955 US11 gene Proteins 0.000 claims description 3
- 101150108190 US2 gene Proteins 0.000 claims description 3
- 101150047715 US3 gene Proteins 0.000 claims description 3
- 101150096955 US6 gene Proteins 0.000 claims description 3
- 230000000692 anti-sense effect Effects 0.000 claims description 3
- 101150036031 gD gene Proteins 0.000 claims description 3
- 230000009368 gene silencing by RNA Effects 0.000 claims description 3
- 108091092562 ribozyme Proteins 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 230000004083 survival effect Effects 0.000 claims 2
- 241000701022 Cytomegalovirus Species 0.000 description 70
- 241000700605 Viruses Species 0.000 description 62
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 20
- 230000003612 virological effect Effects 0.000 description 19
- 108090000288 Glycoproteins Proteins 0.000 description 18
- 102000003886 Glycoproteins Human genes 0.000 description 18
- 201000010099 disease Diseases 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 239000002245 particle Substances 0.000 description 15
- 241001529453 unidentified herpesvirus Species 0.000 description 14
- 210000002889 endothelial cell Anatomy 0.000 description 11
- 230000010076 replication Effects 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 230000002238 attenuated effect Effects 0.000 description 8
- 230000002458 infectious effect Effects 0.000 description 8
- 210000003754 fetus Anatomy 0.000 description 7
- 241001529936 Murinae Species 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 208000030507 AIDS Diseases 0.000 description 5
- 206010010356 Congenital anomaly Diseases 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 230000007420 reactivation Effects 0.000 description 5
- 230000004543 DNA replication Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000001161 mammalian embryo Anatomy 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 206010035742 Pneumonitis Diseases 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 108020005202 Viral DNA Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000234 capsid Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000002101 lytic effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000001850 reproductive effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000010415 tropism Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 206010021882 Infections and infestations congenital Diseases 0.000 description 2
- 241000701029 Murid betaherpesvirus 1 Species 0.000 description 2
- 206010037549 Purpura Diseases 0.000 description 2
- 206010038910 Retinitis Diseases 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 238000011225 antiretroviral therapy Methods 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 231100000888 hearing loss Toxicity 0.000 description 2
- 230000010370 hearing loss Effects 0.000 description 2
- 208000016354 hearing loss disease Diseases 0.000 description 2
- 208000024697 human cytomegalovirus infection Diseases 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 229940124590 live attenuated vaccine Drugs 0.000 description 2
- 229940023012 live-attenuated vaccine Drugs 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010008096 Cerebral atrophy Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010010430 Congenital cytomegalovirus infection Diseases 0.000 description 1
- 206010062343 Congenital infection Diseases 0.000 description 1
- 101150026402 DBP gene Proteins 0.000 description 1
- 101710160937 DNA replication protein Proteins 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 206010011891 Deafness neurosensory Diseases 0.000 description 1
- 208000035976 Developmental Disabilities Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 229940124841 Herpesvirus vaccine Drugs 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 101710205424 Immediate-early protein 1 Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022095 Injection Site reaction Diseases 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 241000710118 Maize chlorotic mottle virus Species 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 101710121070 Protein mesh Proteins 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 1
- 208000031709 Skin Manifestations Diseases 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 101710183015 Trans-activating transcriptional regulatory protein Proteins 0.000 description 1
- 101150019585 UL31 gene Proteins 0.000 description 1
- 101150087430 UL34 gene Proteins 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000005101 cell tropism Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 201000004709 chorioretinitis Diseases 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000009602 intrauterine growth Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 208000004141 microcephaly Diseases 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000037360 nucleotide metabolism Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000003157 protein complementation Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 231100000879 sensorineural hearing loss Toxicity 0.000 description 1
- 208000023573 sensorineural hearing loss disease Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16151—Methods of production or purification of viral material
- C12N2710/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16161—Methods of inactivation or attenuation
- C12N2710/16162—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16511—Roseolovirus, e.g. human herpesvirus 6, 7
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10004751 | 2010-05-05 | ||
| EP10004751 | 2010-05-05 | ||
| EP10005045 | 2010-05-12 | ||
| EP10005045 | 2010-05-12 | ||
| PCT/EP2011/002252 WO2011138040A2 (en) | 2010-05-05 | 2011-05-05 | Vaccine against beta-herpesvirus infection and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2679245T3 true ES2679245T3 (es) | 2018-08-23 |
Family
ID=44146744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11718950.6T Active ES2679245T3 (es) | 2010-05-05 | 2011-05-05 | Vacuna contra la infección por beta-herpesvirus y uso de la misma |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9078867B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2566957B8 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2013527758A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2011250191A1 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2798214C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2679245T3 (cg-RX-API-DMAC7.html) |
| SG (2) | SG10201503450WA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011138040A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2793959C (en) | 2010-03-25 | 2019-06-04 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| SI2772265T1 (en) | 2010-05-14 | 2018-06-29 | Oregon Health & Science University | HCMV AND RHCMV RECOMBINANT VECTORS AND THEIR APPLICATIONS |
| SI2691530T1 (en) | 2011-06-10 | 2018-08-31 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| US20140348863A1 (en) * | 2011-10-12 | 2014-11-27 | Alessia Bianchi | Cmv antigens and uses thereof |
| US20130156808A1 (en) | 2011-11-22 | 2013-06-20 | Stipan Jonjic | Vaccine comprising beta-herpesvirus |
| ES2696703T3 (es) * | 2013-03-05 | 2019-01-17 | Univ Oregon Health & Science | Vectores de citomegalovirus que permiten el control del direccionamiento de los linfocitos T |
| AU2014344807A1 (en) | 2013-10-29 | 2016-05-19 | The University Of Sydney | CMV immuno-stimulatory composition |
| CA3113595A1 (en) | 2014-07-16 | 2016-01-21 | Oregon Health & Science University | Human cytomegalovirus comprising exogenous antigens |
| KR20170136512A (ko) | 2015-02-10 | 2017-12-11 | 오레곤 헬스 앤드 사이언스 유니버시티 | 넌-캐노니컬 cd8+ t 세포 반응 생성에 유용한 방법 및 조성물 |
| CA3005136A1 (en) | 2015-11-20 | 2017-05-26 | Oregon Health & Science University | Cmv vectors comprising microrna recognition elements |
| CA3040303A1 (en) | 2016-10-18 | 2018-04-26 | Oregon Health & Science University | Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules |
| WO2020014222A2 (en) * | 2018-07-09 | 2020-01-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Viral promoters and compositions and methods of use thereof |
| US12276665B2 (en) | 2018-07-20 | 2025-04-15 | Aicuris Anti-Infective Cures Ag | Methods for screening and identifying agents that inhibit or modulate the nuclear egress complex of herpesviruses |
| US20230364215A1 (en) * | 2020-10-02 | 2023-11-16 | Colorado State University Research Foundation | Compositions comprising inactivated microbes, and methods for use and production thereof |
| CN116042526B (zh) * | 2022-07-04 | 2023-11-10 | 北京肿瘤医院(北京大学肿瘤医院) | P16基因特异性甲基化的正常人永生化结肠成纤维细胞 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7374768B1 (en) | 1990-09-25 | 2008-05-20 | Xenova Research Limited | Viral vaccines |
| DE19733364A1 (de) * | 1997-08-01 | 1999-02-04 | Koszinowski Ulrich H Prof | Verfahren zur Klonierung eines großen Virusgenoms |
| US6573090B1 (en) | 1998-12-09 | 2003-06-03 | The General Hospital Corporation | Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors |
| US7407744B2 (en) * | 2003-07-25 | 2008-08-05 | The Regents Of The University Of California | Cytomegalovirus gene function and methods for developing antivirals, anti-CMV vaccines, and CMV-based vectors |
| EP2497831B1 (en) * | 2004-05-25 | 2014-07-16 | Oregon Health and Science University | TB vaccination using HCMV-based vaccine vectors |
-
2011
- 2011-05-05 JP JP2013508401A patent/JP2013527758A/ja active Pending
- 2011-05-05 ES ES11718950.6T patent/ES2679245T3/es active Active
- 2011-05-05 US US13/695,668 patent/US9078867B2/en active Active
- 2011-05-05 CA CA2798214A patent/CA2798214C/en active Active
- 2011-05-05 AU AU2011250191A patent/AU2011250191A1/en not_active Abandoned
- 2011-05-05 SG SG10201503450WA patent/SG10201503450WA/en unknown
- 2011-05-05 WO PCT/EP2011/002252 patent/WO2011138040A2/en not_active Ceased
- 2011-05-05 CA CA3128572A patent/CA3128572C/en active Active
- 2011-05-05 SG SG2012080891A patent/SG185121A1/en unknown
- 2011-05-05 EP EP11718950.6A patent/EP2566957B8/en active Active
-
2015
- 2015-06-09 US US14/734,415 patent/US20150306210A1/en not_active Abandoned
-
2016
- 2016-02-04 JP JP2016019841A patent/JP6427514B2/ja active Active
-
2018
- 2018-11-19 US US16/194,558 patent/US10842863B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011138040A3 (en) | 2012-10-26 |
| JP2013527758A (ja) | 2013-07-04 |
| US20150306210A1 (en) | 2015-10-29 |
| EP2566957A2 (en) | 2013-03-13 |
| CA2798214A1 (en) | 2011-11-10 |
| US10842863B2 (en) | 2020-11-24 |
| EP2566957B8 (en) | 2018-06-06 |
| JP6427514B2 (ja) | 2018-11-21 |
| WO2011138040A8 (en) | 2012-12-20 |
| EP2566957B1 (en) | 2018-04-18 |
| CA3128572C (en) | 2023-02-21 |
| AU2011250191A1 (en) | 2012-11-22 |
| CA2798214C (en) | 2021-10-19 |
| SG185121A1 (en) | 2012-11-29 |
| CA3128572A1 (en) | 2011-11-10 |
| SG10201503450WA (en) | 2015-06-29 |
| US20190117766A1 (en) | 2019-04-25 |
| US20130202638A1 (en) | 2013-08-08 |
| US9078867B2 (en) | 2015-07-14 |
| WO2011138040A2 (en) | 2011-11-10 |
| JP2016136950A (ja) | 2016-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2679245T3 (es) | Vacuna contra la infección por beta-herpesvirus y uso de la misma | |
| Gerna et al. | Human cytomegalovirus (HCMV) infection/re-infection: development of a protective HCMV vaccine | |
| Roark et al. | Animal models of congenital cytomegalovirus transmission: implications for vaccine development | |
| ES2748039T3 (es) | Partículas similares a virus (VLP) de segunda generación a partir de virus de Epstein-Barr para fines de vacunación | |
| JP2024016032A (ja) | 組み換え単純ヘルペスウイルス２（ｈｓｖ－２）ワクチンベクターを使用する免疫の受動伝達 | |
| US10918712B2 (en) | Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors | |
| US20220088185A1 (en) | Passive transfer of immunity using recombinant herpes simplex virus 2 (hsv-2) vaccine vectors | |
| AU2017204774B2 (en) | Vaccine against beta-herpesvirus infection and use thereof | |
| Reina | Current status of vaccines against congenital cytomegalovirus infection: The paradox of previous immunity | |
| Kamel | Development and molecular studies on Equine Herpesvirus type 1 (EHV-1) vaccine against foot and mouth disease virus | |
| Polz-Dacewicz et al. | Cytomegalovirus (CMV)–a new prospect for prevention | |
| Marsh | Characterization and Development of a Novel Cytomegalovirus for Evaluation as an HIV Vaccine Viral Vector in a Non-Human Primate Model | |
| Malavige et al. | Investigation of Varicella Zoster virus Glycoprotein-specific T cell responses |